SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-031927
Filing Date
2019-08-14
Accepted
2019-08-14 06:07:15
Documents
96
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-10q_20190630.htm 10-Q 4225681
2 EX-31.1 bbio-ex311_351.htm EX-31.1 19407
3 EX-31.2 bbio-ex312_350.htm EX-31.2 19498
4 EX-32.1 bbio-ex321_348.htm EX-32.1 11192
5 EX-32.2 bbio-ex322_349.htm EX-32.2 11185
  Complete submission text file 0001564590-19-031927.txt   15347383

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT bbio-20190630.xml EX-101.INS 3897026
7 XBRL TAXONOMY EXTENSION SCHEMA bbio-20190630.xsd EX-101.SCH 93417
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE bbio-20190630_cal.xml EX-101.CAL 50501
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bbio-20190630_def.xml EX-101.DEF 514178
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20190630_lab.xml EX-101.LAB 571180
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20190630_pre.xml EX-101.PRE 645443
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 191022665
SIC: 2834 Pharmaceutical Preparations